• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向蛙皮素受体的脂质体用于增强对肺癌细胞的递送

Bombesin receptor-targeted liposomes for enhanced delivery to lung cancer cells.

作者信息

Akbar Mohammad J, Lukasewicz Ferreira Pâmela C, Giorgetti Melania, Stokes Leanne, Morris Christopher J

机构信息

School of Pharmacy, University of East Anglia, Norwich, UK.

出版信息

Beilstein J Nanotechnol. 2019 Dec 19;10:2553-2562. doi: 10.3762/bjnano.10.246. eCollection 2019.

DOI:10.3762/bjnano.10.246
PMID:31921534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6941431/
Abstract

Gastrin-releasing peptide is a member of the bombesin family of peptides. Its cognate receptor, gastrin releasing peptide receptor (GRPR), is widely expressed in cancers of the lung, pancreas and ovaries. Gastrin releasing peptide (GRP) is an autocrine growth factor in small cell lung cancer, which has very poor patient outcomes. High affinity antagonist peptides have been developed for in vivo cancer imaging. In this report we decorated pegylated liposomes with a GRPR antagonist peptide and studied its interaction with, and accumulation within, lung cancer cells. An N-terminally cysteine modified GRPR antagonist (termed cystabn) was synthesised and shown to inhibit cell growth in vitro. Cystabn was used to prepare a targeted 1,2-distearoyl--glycero-3-phosphoethanolamine--[amino(polyethylene glycol)-2000] (DSPE-PEG2000) lipid conjugate that was formulated into liposomes. The liposomes displayed desirable colloidal properties and good stability under storage conditions. Flow cytometric and microscopic studies showed that fluorescently labelled cystabn-decorated liposomes accumulated more extensively in GRPR over-expressing cells than matched liposomes that contained no cystabn targeting motif. The use of GRPR antagonistic peptides for nanoparticle targeting has potential for enhancing drug accumulation in resistant cancer cells.

摘要

胃泌素释放肽是蛙皮素肽家族的成员。其同源受体,即胃泌素释放肽受体(GRPR),在肺癌、胰腺癌和卵巢癌中广泛表达。胃泌素释放肽(GRP)是小细胞肺癌中的一种自分泌生长因子,这类患者的预后非常差。已经开发出高亲和力拮抗剂肽用于体内癌症成像。在本报告中,我们用GRPR拮抗剂肽修饰聚乙二醇化脂质体,并研究其与肺癌细胞的相互作用以及在肺癌细胞内的积累情况。合成了一种N端半胱氨酸修饰的GRPR拮抗剂(称为cystabn),并证明其在体外可抑制细胞生长。使用cystabn制备了靶向1,2 - 二硬脂酰 - sn -甘油 - 3 - 磷酸乙醇胺 - [氨基(聚乙二醇)- 2000](DSPE - PEG2000)脂质缀合物,并将其制成脂质体。这些脂质体在储存条件下表现出理想的胶体性质和良好的稳定性。流式细胞术和显微镜研究表明,与不含cystabn靶向基序的对照脂质体相比,荧光标记的cystabn修饰脂质体在GRPR过表达细胞中的积累更为广泛。使用GRPR拮抗肽进行纳米颗粒靶向具有增强耐药癌细胞中药物积累的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/a11c32217456/Beilstein_J_Nanotechnol-10-2553-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/488f2bbd7ec3/Beilstein_J_Nanotechnol-10-2553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/ec90a5311ad0/Beilstein_J_Nanotechnol-10-2553-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/f1486750a538/Beilstein_J_Nanotechnol-10-2553-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/a11c32217456/Beilstein_J_Nanotechnol-10-2553-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/488f2bbd7ec3/Beilstein_J_Nanotechnol-10-2553-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/ec90a5311ad0/Beilstein_J_Nanotechnol-10-2553-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/f1486750a538/Beilstein_J_Nanotechnol-10-2553-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/6941431/a11c32217456/Beilstein_J_Nanotechnol-10-2553-g005.jpg

相似文献

1
Bombesin receptor-targeted liposomes for enhanced delivery to lung cancer cells.靶向蛙皮素受体的脂质体用于增强对肺癌细胞的递送
Beilstein J Nanotechnol. 2019 Dec 19;10:2553-2562. doi: 10.3762/bjnano.10.246. eCollection 2019.
2
Investigation of bombesin peptide as a targeting ligand for the gastrin releasing peptide (GRP) receptor.将蛙皮素肽作为胃泌素释放肽(GRP)受体的靶向配体进行研究。
Bioorg Med Chem. 2016 Nov 15;24(22):5834-5841. doi: 10.1016/j.bmc.2016.09.039. Epub 2016 Sep 16.
3
Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer.神经介素B和胃泌素释放肽在非小细胞肺癌中的自分泌作用证据。
Pulm Pharmacol Ther. 1999;12(5):291-302. doi: 10.1006/pupt.1999.0210.
4
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.脂质-聚合物杂化纳米颗粒作为新一代治疗性递送平台:综述
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43. doi: 10.1016/j.ejpb.2013.07.002. Epub 2013 Jul 17.
5
N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.N 端修饰可提高放射性标记的肽类胃泌素释放肽受体拮抗剂的受体亲和力和药代动力学:用于正电子发射断层显像(PET)的68Ga和64Cu标记肽的实例
J Nucl Med. 2014 Oct;55(10):1719-25. doi: 10.2967/jnumed.114.141242. Epub 2014 Aug 21.
6
Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.(177)Lu标记的糖化蛙皮素类似物用于胃泌素释放肽受体阳性前列腺肿瘤靶向的临床前药代动力学、生物分布、成像及治疗效果
Nucl Med Biol. 2015 Mar;42(3):234-41. doi: 10.1016/j.nucmedbio.2014.10.008. Epub 2014 Oct 22.
7
The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.大环螯合剂对68Ga标记的胃泌素释放肽受体拮抗剂PEG2-RM26靶向特性的影响
Nucl Med Biol. 2015 May;42(5):446-454. doi: 10.1016/j.nucmedbio.2014.12.009. Epub 2014 Dec 20.
8
Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.载紫杉醇的具有线粒体靶向和 pH 响应双重功能的脂质体克服耐药性肺癌。
Biomaterials. 2015 Jun;52:126-39. doi: 10.1016/j.biomaterials.2015.02.004. Epub 2015 Feb 24.
9
Supercritical fluid assembly of albendazole liposomes targeting gastrin-releasing peptide receptor overexpressing tumors.针对过表达胃泌素释放肽受体的肿瘤的阿苯达唑脂质体的超临界流体组装。
Nanomedicine (Lond). 2020 Jun 2. doi: 10.2217/nnm-2020-0048.
10
Oestrone-targeted liposomes for mitoxantrone delivery via oestrogen receptor - synthesis, physicochemical characterization and in-vitro evaluation.用于通过雌激素受体递送米托蒽醌的靶向雌酮脂质体——合成、理化特性及体外评价
J Pharm Pharmacol. 2017 Aug;69(8):991-1001. doi: 10.1111/jphp.12736. Epub 2017 Apr 26.

引用本文的文献

1
Silencing IFIT3 suppresses the EGFR/VEGF pathway and modulates SOCS1 to attenuate skin fibrosis in systemic sclerosis.沉默IFIT3可抑制EGFR/VEGF通路并调节SOCS1以减轻系统性硬化症中的皮肤纤维化。
Apoptosis. 2025 Jun 14. doi: 10.1007/s10495-025-02115-y.
2
YTHDF1-mediated m6A modification promotes cisplatin resistance in ovarian cancer via the FZD7/Wnt/β-catenin pathway.YTHDF1介导的m6A修饰通过FZD7/ Wnt/β-连环蛋白途径促进卵巢癌顺铂耐药。
Apoptosis. 2025 Apr 26. doi: 10.1007/s10495-025-02094-0.
3
GRPR Drives Metastasis via CRABP2 and FNDC4 Pathways in Lung Adenocarcinoma.

本文引用的文献

1
Lipid Switches: Stimuli-Responsive Liposomes through Conformational Isomerism Driven by Molecular Recognition.脂质开关:通过分子识别驱动的构象互变实现刺激响应的脂质体。
Chemistry. 2019 Jan 2;25(1):20-25. doi: 10.1002/chem.201803389. Epub 2018 Nov 26.
2
A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.一种可能的肺癌细胞新靶点:孤儿受体,蛙皮素受体亚型 3。
Peptides. 2018 Mar;101:213-226. doi: 10.1016/j.peptides.2018.01.016. Epub 2018 Feb 2.
3
AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.
胃泌素释放肽受体(GRPR)通过CRABP2和FNDC4途径驱动肺腺癌转移。
Cells. 2024 Dec 23;13(24):2128. doi: 10.3390/cells13242128.
4
SIRT1-mediated deacetylation of FOXO3 enhances mitophagy and drives hormone resistance in endometrial cancer.SIRT1 介导的 FOXO3 去乙酰化增强了子宫内膜癌细胞的线粒体自噬作用,并导致了激素抵抗。
Mol Med. 2024 Sep 12;30(1):147. doi: 10.1186/s10020-024-00915-7.
5
Synergistic vesicle-vector systems for targeted delivery.协同囊泡载体系统用于靶向递药。
J Nanobiotechnology. 2024 Jan 3;22(1):6. doi: 10.1186/s12951-023-02275-6.
6
Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor.纳米策略用于胃泌素释放肽受体的治疗和诊断靶向。
Int J Mol Sci. 2023 Feb 9;24(4):3455. doi: 10.3390/ijms24043455.
7
Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide-Drug Conjugates.靶向胃泌素释放肽受体(GRP-R)在癌症治疗中的应用:基于蛙皮素的肽药物偶联物的开发。
Int J Mol Sci. 2023 Feb 8;24(4):3400. doi: 10.3390/ijms24043400.
8
Structures of human gastrin-releasing peptide receptors bound to antagonist and agonist for cancer and itch therapy.与人胃泌素释放肽受体结合的拮抗剂和激动剂的结构用于癌症和瘙痒症的治疗。
Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2216230120. doi: 10.1073/pnas.2216230120. Epub 2023 Feb 1.
9
Bombesin-drug conjugates in targeted therapy for small cell lung cancer.蛙皮素-药物偶联物在小细胞肺癌靶向治疗中的应用
Am J Cancer Res. 2022 Mar 15;12(3):927-937. eCollection 2022.
10
Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy.脂质体纳米药物:在癌症治疗中用于药物递送的应用
Nanoscale Res Lett. 2021 May 25;16(1):95. doi: 10.1186/s11671-021-03553-8.
AM - 37和ST - 36是小分子蛙皮素受体拮抗剂。
Front Endocrinol (Lausanne). 2017 Jul 21;8:176. doi: 10.3389/fendo.2017.00176. eCollection 2017.
4
Unravelling the biology of SCLC: implications for therapy.揭示小细胞肺癌的生物学特性:对治疗的启示
Nat Rev Clin Oncol. 2017 Sep;14(9):549-561. doi: 10.1038/nrclinonc.2017.71. Epub 2017 May 23.
5
To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes.加热还是不加热:热敏脂质体临床转化面临的挑战。
J Control Release. 2017 Mar 10;249:63-73. doi: 10.1016/j.jconrel.2017.01.025. Epub 2017 Jan 22.
6
Cancer nanomedicine: progress, challenges and opportunities.癌症纳米医学:进展、挑战与机遇。
Nat Rev Cancer. 2017 Jan;17(1):20-37. doi: 10.1038/nrc.2016.108. Epub 2016 Nov 11.
7
Bombesin-Targeted PET of Prostate Cancer.前列腺癌的蛙皮素靶向正电子发射断层显像
J Nucl Med. 2016 Oct;57(Suppl 3):67S-72S. doi: 10.2967/jnumed.115.170977.
8
The protein corona of circulating PEGylated liposomes.循环聚乙二醇化脂质体的蛋白质冠层。
Biochim Biophys Acta. 2016 Feb;1858(2):189-96. doi: 10.1016/j.bbamem.2015.11.012. Epub 2015 Nov 19.
9
68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients.68Ga-NOTA-Aca-BBN(7-14) PET/CT 在健康志愿者和脑胶质瘤患者中的应用。
J Nucl Med. 2016 Jan;57(1):9-14. doi: 10.2967/jnumed.115.165316. Epub 2015 Oct 8.
10
Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumors.评估三种不同家族的蛙皮素受体放射性拮抗剂用于胃泌素释放肽受体(GRP-R)阳性肿瘤的靶向成像和治疗。
J Med Chem. 2015 Jan 22;58(2):682-91. doi: 10.1021/jm5012066. Epub 2014 Dec 17.